Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Sai Ping LauFreek R van 't LandSjoerd H van der BurgMarjolein Y V HomsMartijn P LolkemaJoachim G J V AertsCasper H J van EijckPublished in: BMJ open (2022)
NL9723.